AIM: To evaluate whether individuals with gastric cancer(GC) are diagnosed earlier if they have firstdegree relatives with ***: A total of 4282 patients diagnosed with GC at National Cancer Center Hospital from 2002 t...
详细信息
AIM: To evaluate whether individuals with gastric cancer(GC) are diagnosed earlier if they have firstdegree relatives with ***: A total of 4282 patients diagnosed with GC at National Cancer Center Hospital from 2002 to 2012 were enrolled in this retrospective study. We classified the patients according to presence or absence of first-degree family history of GC and compared age at diagnosis and clinicopathologic characteristics. In addition, we further classified patients according to specific family member with GC(father, mother, sibling, or offspring) and compared age at GC diagnosis among these patient groups. Baseline characteristics were obtained from a prospectively collected database. Information about the family member's age at GC diagnosis was obtained by ***: A total of 924 patients(21.6%) had a firstdegree family history of GC. The mean age at GC diagnosis in patients having paternal history of GC was 54.4 ± 10.4 years and was significantly younger than in those without a first-degree family history(58.1 ± 12.0 years, P < 0.001). However, this finding was not observed in patients who had an affected mother(57.2 ± 10.0 years) or sibling(62.2 ± 9.8 years). Among patients with family member having early-onset GC(< 50 years old), mean age at diagnosis was 47.7 ± 10.3 years for those with an affected father, 48.6 ± 10.4 years for those with an affected mother, and 57.4 ± 11.5 years for those with an affected sibling. Thus, patients with a parent diagnosed before 50 years of age developed GC 10.4 or 9.5 years earlier than individuals without a family history of GC(both P <0.001).CONCLUSION: Early-onset GC before age of 50 was associated with parental history of early-onset of GC. Individual having such family history need to start screening earlier.
In the last few decades,adverse reactions to pharmaceuticals have been evaluated using 2D in vitro models and animal ***,with increasing computational power,and as the key drivers of cellular behavior have been identi...
详细信息
In the last few decades,adverse reactions to pharmaceuticals have been evaluated using 2D in vitro models and animal ***,with increasing computational power,and as the key drivers of cellular behavior have been identified,in silico models have *** models are time-efficient and cost-effective,but the prediction of adverse reactions to unknown drugs using these models requires relevant experimental ***,the physiome concept has emerged to bridge experimental datasets with in silico *** brain physiome describes the systemic interactions of its components,which are organized into a multilevel *** of the limitations in obtaining experimental data corresponding to each physiome component from 2D in vitro models and animal models,3D in vitro brain models,including brain organoids and brain-on-a-chip,have been *** this review,we present the concept of the brain physiome and its hierarchical organization,including cell-and tissue-level *** also summarize recently developed 3D in vitro brain models and link them with the elements of the brain physiome as a guideline for dataset *** connection between in vitro 3D brain models and in silico modeling will lead to the establishment of cost-effective and time-efficient in silico models for the prediction of the safety of unknown drugs.
暂无评论